PharmaEssentia (6446)

Currency in TWD
640.00
-6.00(-0.93%)
Closed·
6446 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
640.00654.00
52 wk Range
440.00780.00
Key Statistics
Bid/Ask
91.40 / 91.50
Prev. Close
565
Open
647
Day's Range
640-654
52 wk Range
440-780
Volume
1.5M
Average Volume (3m)
3.23M
1-Year Change
10.7266%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6446 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
757.00
Upside
+18.28%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

PharmaEssentia News & Analysis

Show more

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Employees
131
Market
Taiwan

Compare 6446 to Peers and Sector

Metrics to compare
6446
Peers
Sector
Relationship
P/E Ratio
47.1x0.0x−0.5x
PEG Ratio
0.670.000.00
Price/Book
7.4x0.0x2.6x
Price / LTM Sales
15.2x0.0x3.1x
Upside (Analyst Target)
9.4%0.0%57.5%
Fair Value Upside
Unlock0.0%8.6%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 757.00
(+18.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 13.59%
Dividend Yield
0.18%
Industry Median 0.75%
Annualized payout
0.99
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Mar 02, 2026
EPS / Forecast
3.98 / 4.21
Revenue / Forecast
4.88B / 4.48B
EPS Revisions
Last 90 days

6446 Income Statement

People Also Watch

110.00
2344
-9.84%
1,915.00
8299
-2.30%
222.00
2313
-0.67%
988.00
2368
-1.69%
1,825.00
3665
+6.10%

FAQ

What Is the PharmaEssentia (6446) Stock Price Today?

The PharmaEssentia stock price today is 640.00 TWD.

What Stock Exchange Does PharmaEssentia Trade On?

PharmaEssentia is listed and trades on the Taiwan Stock Exchange.

What Is the Stock Symbol for PharmaEssentia?

The stock symbol for PharmaEssentia is "6446."

Does PharmaEssentia Pay Dividends? What’s The Current Dividend Yield?

The PharmaEssentia dividend yield is 0.18%.

What Is the PharmaEssentia Market Cap?

As of today, PharmaEssentia market cap is 237.54B TWD.

What Is PharmaEssentia's Earnings Per Share (TTM)?

The PharmaEssentia EPS (TTM) is 13.59.

When Is the Next PharmaEssentia Earnings Date?

PharmaEssentia will release its next earnings report on May 08, 2026.

From a Technical Analysis Perspective, Is 6446 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has PharmaEssentia Stock Split?

PharmaEssentia has split 3 times.

How Many Employees Does PharmaEssentia Have?

PharmaEssentia has 131 employees.

What is the current trading status of PharmaEssentia (6446)?

As of Mar 22, 2026, PharmaEssentia (6446) is trading at a price of 640.00 TWD, with a previous close of 565.00 TWD. The stock has fluctuated within a day range of 640.00 TWD to 654.00 TWD, while its 52-week range spans from 440.00 TWD to 780.00 TWD.

What Is PharmaEssentia (6446) Price Target According to Analysts?

The average 12-month price target for PharmaEssentia is 757.00 TWD, with a high estimate of 1090 TWD and a low estimate of 550 TWD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +18.28% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.